A Normal Inhibitor of the Blood Coagulation Contact Reaction Product.

In Vitro and in Vivo studies of the Effects of Cold Argon Plasma on Decreasing the Coagulation Time

Introduction Cold plasma is a self-sterilized, painless, and non-contact method in surgeries. These properties allow it to be applied to the living tissues and heat-sensitive parts. The aim of this study was to design a new cold plasma producer device and evaluate the effects of cold argon plasma on decreasing the coagulation time of blood drop in vitro and that of the injured liver blood in vi...

FACTOR V AND VIII INHIBITOR IN PATIENTS WITH COMBINED FACTOR V AND VIII DEFICIENCY

Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...

Coagulation Therapy in Hemophilia A and its Relation to Factor VIII Inhibitor in Northeast of Iran

Cold-induced contact surface activation of the prothrombin time in whole blood.

Studies of the prothrombin time (PT) have revealed that contact with borosilicate or commercial siliconized borosilicate markedly shortens the PT. This shortening is related to the activation of the contact phase of blood coagulation. This shortening of the PT occurs in both normal whole blood and plasma when stored in borosilicate or siliconized borosilicate tubes at 4 degree C and to a lesser...

Evaluation of the Relationship Between Factor IX Inhibitor in Hemophilia B Patients and Different Types of Therapy in the North-eastern Part of Iran

Background: Hemophilia B is a bleeding disorder with a recessive X-linked inheritance pattern, in which the infected individuals have low levels of factor IX in their plasma. Affected individuals may have bleeding episodes after trauma or spontaneously considering the plasma level of factor IX. In order to prevent these episodes and to control bleeding, they should use coagulation factor concen...